Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab

INTRODUCTION: Intraocular inflammation (IOI)-related adverse events (AEs) that may result in severe vision loss have been associated with the anti-vascular endothelial growth factor brolucizumab. In this study, we investigate the timing, management and resolution of IOI-related AEs in a large cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubricky, Ryan, McCoy, Jasmyne, Donkor, Richard, Miller, David G., Sonbolian, Nina, Heaney, Andrew, Bilano, Ver, Karcher, Helene, Coney, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442012/
https://www.ncbi.nlm.nih.gov/pubmed/37310683
http://dx.doi.org/10.1007/s40123-023-00741-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442012/
https://www.ncbi.nlm.nih.gov/pubmed/37310683
http://dx.doi.org/10.1007/s40123-023-00741-w

Ejemplares similares